Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the mechanisms underlying the plasma glucose level-lowering effects of metformin (1,1-dimethylbiguanide) still remain incompletely understood. Metformin is thought to exert its primary antidiabetic action through the suppression of hepatic glucose production. In addition, the discovery that metformin inhibits the mitochondrial respiratory chain complex 1 has placed energy metabolism and activation of AMP-activated protein kinase (AMPK) at the centre of its proposed mechanism of action. However, the role of AMPK has been challenged and might only account for indirect changes in hepatic insulin sensitivity. Various mechanisms involving alterations in cellular energy charge, AMP-mediated inhibition of adenylate cyclase or fructose-1,6-bisphosphatase 1 and modulation of the cellular redox state through direct inhibition of mitochondrial glycerol-3-phosphate dehydrogenase have been proposed for the acute inhibition of gluconeogenesis by metformin. Emerging evidence suggests that metformin could improve obesity-induced meta-inflammation via direct and indirect effects on tissue-resident immune cells in metabolic organs (that is, adipose tissue, the gastrointestinal tract and the liver). Furthermore, the gastrointestinal tract also has a major role in metformin action through modulation of glucose-lowering hormone glucagon-like peptide 1 and the intestinal bile acid pool and alterations in gut microbiota composition.
Metformin is the first-line drug for treatment of type 2 diabetes mellitus, with an excellent safety profile, high efficacy in glycaemic control and clear but incompletely understood cardioprotective benefits.
The pleiotropic properties of metformin suggest that the drug acts on multiple tissues through various underlying mechanisms rather than on a single organ via a unifying mode of action.
Mitochondrial respiratory chain complex 1 is targeted by metformin and its inhibition is involved in AMP-activated protein kinase-independent regulation of hepatic gluconeogenesis by triggering alterations in cellular energy charge and redox state.
Metformin might contribute to improvements in obesity-associated meta-inflammation and tissue-specific insulin sensitivity through direct and indirect effects on various resident immune cells in metabolic organs.
The gastrointestinal tract has an important role in the action of metformin, which modulates bile acid recirculation and enhances the secretion of the glucose-lowering gut incretin hormone glucagon-like peptide 1.
The gut microbiota is a novel target in the mechanisms of metformin action and is involved in both the therapeutic and adverse effects of the drug.
Your institute does not have access to this article
Open Access articles citing this article.
Metformin combats high glucose-induced damage to the osteogenic differentiation of human periodontal ligament stem cells via inhibition of the NPR3-mediated MAPK pathway
Stem Cell Research & Therapy Open Access 15 July 2022
Nature Open Access 23 February 2022
Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study
Reproductive Biology and Endocrinology Open Access 07 February 2022
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41, 2669–2701 (2018).
Davies, M. J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61, 2461–2498 (2018).
United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854–865 (1998).
United Kingdom Prospective Diabetes Study (UKPDS) Group. United Kingdom prospective diabetes study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann. Intern. Med. 128, 165–175 (1998).
Maruthur, N. M. et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med. 164, 740–751 (2016).
Palmer, S. C. et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316, 313–324 (2016).
Sanchez-Rangel, E. & Inzucchi, S. E. Metformin: clinical use in type 2 diabetes. Diabetologia 60, 1586–1593 (2017).
Howlett, H. C. & Bailey, C. J. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf. 20, 489–503 (1999).
Bailey, C. J. Metformin: historical overview. Diabetologia 60, 1566–1576 (2017).
Werner, E. & Bell, J. The preparation of methylguanidine, and of ββ-dimethylguanidine by interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively. J. Am. Chem. Soc. 121, 1790–1794 (1922).
Nattrass, M. et al. Hyperlactatemia in diabetics with retinopathy during combined sulphonylurea and phenformin therapy. Diabete Metab. 4, 1–4 (1978).
Foretz, M., Guigas, B., Bertrand, L., Pollak, M. & Viollet, B. Metformin: from mechanisms of action to therapies. Cell Metab. 20, 953–966 (2014).
Hundal, R. S. et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49, 2063–2069 (2000).
Cusi, K., Consoli, A. & DeFronzo, R. A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81, 4059–4067 (1996).
Hother-Nielsen, O., Schmitz, O., Andersen, P. H., Beck-Nielsen, H. & Pedersen, O. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol. 120, 257–265 (1989).
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G. & Gerich, J. E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333, 550–554 (1995).
DeFronzo, R. A., Barzilai, N. & Simonson, D. C. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J. Clin. Endocrinol. Metab. 73, 1294–1301 (1991).
Inzucchi, S. E. et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med. 338, 867–872 (1998).
Bailey, C. J., Mynett, K. J. & Page, T. Importance of the intestine as a site of metformin-stimulated glucose utilization. Br. J. Pharmacol. 112, 671–675 (1994).
Buse, J. B. et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care 39, 198–205 (2016). This human study provides strong evidence for a gut-mediated mechanism in the blood glucose-lowering action of metformin.
McCreight, L. J., Bailey, C. J. & Pearson, E. R. Metformin and the gastrointestinal tract. Diabetologia 59, 426–435 (2016).
Forslund, K. et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262–266 (2015).
Hardie, D. G. AMPK-sensing energy while talking to other signaling pathways. Cell Metab. 20, 939–952 (2014).
Cao, J. et al. Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK). J. Biol. Chem. 289, 20435–20446 (2014).
Graham, G. G. et al. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 50, 81–98 (2011).
Tucker, G. T. et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br. J. Clin. Pharmacol. 12, 235–246 (1981).
Wilcock, C. & Bailey, C. J. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24, 49–57 (1994).
Jensen, J. B. et al. [11C]-Labeled metformin distribution in the liver and small intestine using dynamic positron emission tomography in mice demonstrates tissue-specific transporter dependency. Diabetes 65, 1724–1730 (2016).
Gormsen, L. C. et al. In vivo imaging of human 11C-metformin in peripheral organs: dosimetry, biodistribution, and kinetic analyses. J. Nucl. Med. 57, 1920–1926 (2016).
Liang, X. & Giacomini, K. M. Transporters involved in metformin pharmacokinetics and treatment response. J. Pharm. Sci. 106, 2245–2250 (2017).
Todd, J. N. & Florez, J. C. An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics 15, 529–539 (2014).
Dujic, T. et al. Variants in pharmacokinetic transporters and glycemic response to metformin: a Metgen meta-analysis. Clin. Pharmacol. Ther. 101, 763–772 (2017).
Zhou, K. et al. Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat. Genet. 48, 1055–1059 (2016).
Ait-Omar, A. et al. GLUT2 accumulation in enterocyte apical and intracellular membranes: a study in morbidly obese human subjects and ob/ob and high fat-fed mice. Diabetes 60, 2598–2607 (2011).
Jablonski, K. A. et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 59, 2672–2681 (2010).
Hollunger, G. Guanidines and oxidative phosphorylations. Acta Pharmacol. Toxicol. 11, 1–84 (1955).
Schafer, G. Site-specific uncoupling and inhibition of oxidative phosphorylation by biguanides. II. Biochim. Biophys. Acta 172, 334–337 (1969).
El-Mir, M. Y. et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275, 223–228 (2000).
Owen, M. R., Doran, E. & Halestrap, A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348, 607–614 (2000). This study together with El-Mir et al. (2000) were the first to report specific inhibition of metformin on the mitochondrial respiratory chain complex 1.
Degli Esposti, M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim. Biophys. Acta 1364, 222–235 (1998).
Fontaine, E. Metformin-induced mitochondrial complex I inhibition: facts, uncertainties, and consequences. Front. Endocrinol. 9, 753 (2018).
Vial, G., Detaille, D. & Guigas, B. Role of mitochondria in the mechanism(s) of action of metformin. Front. Endocrinol. 10, 294 (2019).
Stephenne, X. et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 54, 3101–3110 (2011). The is the first study to show that metformin inhibits mitochondrial respiratory chain complex 1 and activates AMPK in primary human hepatocytes.
Andrzejewski, S., Gravel, S. P., Pollak, M. & St-Pierre, J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab. 2, 12 (2014).
Bridges, H. R., Jones, A. J., Pollak, M. N. & Hirst, J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem. J. 462, 475–487 (2014). This elegant study dissects the mechanism by which metformin inhibits the mitochondrial respiratory chain complex 1.
Guigas, B. et al. Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem. J. 382, 877–884 (2004).
Wheaton, W. W. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 3, e02242 (2014).
Zannella, V. E. et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin. Cancer Res. 19, 6741–6750 (2013).
Gui, D. Y. et al. Environment dictates dependence on mitochondrial complex I for NAD+ and aspartate production and determines cancer cell sensitivity to metformin. Cell Metab. 24, 716–727 (2016).
Cheng, G. et al. Mitochondria-targeted analogues of metformin exhibit enhanced antiproliferative and radiosensitizing effects in pancreatic cancer cells. Cancer Res. 76, 3904–3915 (2016).
Boukalova, S. et al. Mitochondrial targeting of metformin enhances its activity against pancreatic cancer. Mol. Cancer Ther. 15, 2875–2886 (2016).
Guo, Z. et al. Heme binding biguanides target cytochrome P450-dependent cancer cell mitochondria. Cell Chem. Biol. 24, 1314–1275.e6 (2017).
Thakur, S. et al. Metformin targets mitochondrial glycerophosphate dehydrogenase to control rate of oxidative phosphorylation and growth of thyroid cancer in vitro and in vivo. Clin. Cancer Res. 24, 4030–4043 (2018).
Fontaine, E. Metformin and respiratory chain complex I: the last piece of the puzzle? Biochem. J. 463, e3–e5 (2014).
Wilcock, C., Wyre, N. D. & Bailey, C. J. Subcellular distribution of metformin in rat liver. J. Pharm. Pharmacol. 43, 442–444 (1991).
Detaille, D. et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 54, 2179–2187 (2005). This is the first study demonstrating that metformin can reduce oxidative stress through its mitochondrial action.
Detaille, D., Guigas, B., Leverve, X., Wiernsperger, N. & Devos, P. Obligatory role of membrane events in the regulatory effect of metformin on the respiratory chain function. Biochem. Pharmacol. 63, 1259–1272 (2002).
El-Mir, M. Y. et al. Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J. Mol. Neurosci. 34, 77–87 (2008).
Bridges, H. R., Sirvio, V. A., Agip, A. N. & Hirst, J. Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase. BMC Biol. 14, 65 (2016).
Logie, L. et al. Cellular responses to the metal-binding properties of metformin. Diabetes 61, 1423–1433 (2012).
Hirst, J. Mitochondrial complex I. Annu. Rev. Biochem. 82, 551–575 (2013).
Zickermann, V. et al. Structural biology. Mechanistic insight from the crystal structure of mitochondrial complex I. Science 347, 44–49 (2015).
Saheki, T. et al. Citrin/mitochondrial glycerol-3-phosphate dehydrogenase double knock-out mice recapitulate features of human citrin deficiency. J. Biol. Chem. 282, 25041–25052 (2007).
Shu, Y. et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422–1431 (2007).
He, L. & Wondisford, F. E. Metformin action: concentrations matter. Cell Metab. 21, 159–162 (2015).
Christensen, M. M. et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet. Genomics 21, 837–850 (2011).
Lalau, J. D., Lemaire-Hurtel, A. S. & Lacroix, C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin. Drug Investig. 31, 435–438 (2011).
Foretz, M. et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120, 2355–2369 (2010). This paper provides genetic evidence of AMPK-independent action of metformin in the inhibition of hepatic glucose production.
Fullerton, M. D. et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 19, 1649–1654 (2013). This paper provides genetic evidence of AMPK-mediated phosphorylation of both ACC1 and ACC2 in metformin regulation of lipid metabolism and insulin sensitivity.
Hunter, R. W. et al. Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. Nat. Med. 24, 1395–1406 (2018). This study provides genetic evidence of metformin inhibition of hepatic glucose production through allosteric inhibition of fructose-1-6-bisphosphatase via metformin-induced increases of intracellular AMP levels.
Miller, R. A. et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494, 256–260 (2013). This paper describes the suppression of hepatic glucagon signalling in response to metformin by inhibition of adenylate cyclase via metformin-induced increases of intracellular AMP levels.
Clarke, J. D. et al. Mechanism of altered metformin distribution in nonalcoholic steatohepatitis. Diabetes 64, 3305–3313 (2015).
Scheen, A. J. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 30, 359–371 (1996).
Alshawi, A. & Agius, L. Low metformin causes a more oxidized mitochondrial NADH/NAD redox state in hepatocytes and inhibits gluconeogenesis by a redox-independent mechanism. J. Biol. Chem. 294, 2839–2853 (2019).
Madiraju, A. K. et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542–546 (2014). This paper describes a redox-dependent mechanism to account for the inhibition of hepatic gluconeogenesis by metformin.
Al-Oanzi, Z. H. et al. Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes. Diabetes Obes. Metab. 19, 1078–1087 (2017).
Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174 (2001). This is the first paper showing AMPK activation by metformin.
Hawley, S. A. et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 11, 554–565 (2010).
Zhang, C. S. et al. The lysosomal v-ATPase-ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. Cell Metab. 20, 526–540 (2014). This study reports an AMP-independent mechanism for glucose sensing by AMPK through the lysosomal pathway.
Li, M. et al. Transient receptor potential V channels are essential for glucose sensing by aldolase and AMPK. Cell Metab. https://doi.org/10.1016/j.cmet.2019.05.018 (2019).
Zhang, C. S. et al. Metformin activates AMPK through the lysosomal pathway. Cell Metab. 24, 521–522 (2016).
Shaw, R. J. et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642–1646 (2005).
He, L. et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137, 635–646 (2009).
Lee, J. M. et al. AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner. J. Biol. Chem. 285, 32182–32191 (2010).
Caton, P. W. et al. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J. Endocrinol. 205, 97–106 (2010).
Boudaba, N. et al. AMPK re-activation suppresses hepatic steatosis but its downregulation does not promote fatty liver development. EBioMedicine 28, 194–209 (2018). This paper provides genetic evidence of AMPK-dependent effects of metformin on lipogenesis inhibition and fatty acid oxidation stimulation.
Cokorinos, E. C. et al. Activation of skeletal muscle AMPK promotes glucose disposal and glucose lowering in non-human primates and mice. Cell Metab. 25, 1147–1159.e10 (2017). This study provides pharmacological and genetic evidence of the blood glucose-lowering effect of AMPK activation in skeletal muscle.
Madiraju, A. K. et al. Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat. Med. 24, 1384–1394 (2018).
Ringler, R. L. & Singer, T. P. Studies on the mitochondrial alpha-glycerophosphate dehydrogenase. I. Reaction of the dehydrogenase with electron acceptors and the respiratory chain. J. Biol. Chem. 234, 2211–2217 (1959).
Lee, Y. P. & Lardy, H. A. Influence of thyroid hormones on L-α-glycerophosphate dehydrogenases and other dehydrogenases in various organs of the rat. J. Biol. Chem. 240, 1427–1436 (1965).
Lin, E. C. Glycerol utilization and its regulation in mammals. Annu. Rev. Biochem. 46, 765–795 (1977).
Brisson, D., Vohl, M. C., St-Pierre, J., Hudson, T. J. & Gaudet, D. Glycerol: a neglected variable in metabolic processes? Bioessays 23, 534–542 (2001).
Baur, J. A. & Birnbaum, M. J. Control of gluconeogenesis by metformin: does redox trump energy charge? Cell Metab. 20, 197–199 (2014).
Cool, B. et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3, 403–416 (2006). This is the first paper describing a small-molecule direct AMPK activator.
Esquejo, R. M. et al. Activation of liver AMPK with PF-06409577 corrects NAFLD and lowers cholesterol in rodent and primate preclinical models. EBioMedicine 31, 122–132 (2018).
Mazza, A. et al. The role of metformin in the management of NAFLD. Exp. Diabetes Res. 2012, 716404 (2012).
Hotamisligil, G. S. Inflammation, metaflammation and immunometabolic disorders. Nature 542, 177–185 (2017).
Brestoff, J. R. & Artis, D. Immune regulation of metabolic homeostasis in health and disease. Cell 161, 146–160 (2015).
Lackey, D. E. & Olefsky, J. M. Regulation of metabolism by the innate immune system. Nat. Rev. Endocrinol. 12, 15–28 (2016).
McNelis, J. C. & Olefsky, J. M. Macrophages, immunity, and metabolic disease. Immunity 41, 36–48 (2014).
Lumeng, C. N., Bodzin, J. L. & Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175–184 (2007).
Huang, W. et al. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 59, 347–357 (2010).
Lanthier, N. et al. Kupffer cell activation is a causal factor for hepatic insulin resistance. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G107–G116 (2010).
Talukdar, S. et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat. Med. 18, 1407–1412 (2012).
Cai, D. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med. 11, 183–190 (2005).
Kang, K. et al. Adipocyte-derived Th2 cytokines and myeloid PPARδ regulate macrophage polarization and insulin sensitivity. Cell Metab. 7, 485–495 (2008).
Odegaard, J. I. et al. Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance. Cell Metab. 7, 496–507 (2008).
Ricardo-Gonzalez, R. R. et al. IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity. Proc. Natl Acad. Sci. USA 107, 22617–22622 (2010).
Stanya, K. J. et al. Direct control of hepatic glucose production by interleukin-13 in mice. J. Clin. Invest. 123, 261–271 (2013).
Odegaard, J. I. et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 447, 1116–1120 (2007).
Ilan, Y. et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc. Natl Acad. Sci. USA 107, 9765–9770 (2010).
Feuerer, M. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15, 930–939 (2009).
Evia-Viscarra, M. L. et al. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J. Pediatr. Endocrinol. Metab. 25, 41–49 (2012).
Fidan, E. et al. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol. 48, 297–302 (2011).
Cameron, A. R. et al. Anti-inflammatory effects of metformin irrespective of diabetes status. Circ. Res. 119, 652–665 (2016). This study shows some beneficial anti-inflammatory effects of metformin in humans, irrespective of their diabetic status.
Lu, C. H., Hung, Y. J. & Hsieh, P. S. Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. Eur. J. Pharmacol. 789, 60–67 (2016).
Xue, W. et al. Alkannin inhibited hepatic inflammation in diabetic Db/Db mice. Cell. Physiol. Biochem. 45, 2461–2470 (2018).
Shen, C. L. et al. Annatto-extracted tocotrienols improve glucose homeostasis and bone properties in high-fat diet-induced type 2 diabetic mice by decreasing the inflammatory response. Sci. Rep. 8, 11377 (2018).
Jing, Y. et al. Metformin improves obesity-associated inflammation by altering macrophages polarization. Mol. Cell. Endocrinol. 461, 256–264 (2018).
de Oliveira, S. et al. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. J. Hepatol. 70, 710-721(2018).
Kim, J. et al. Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction. J. Biol. Chem. 289, 23246–23255 (2014).
Kelly, B., Tannahill, G. M., Murphy, M. P. & O’Neill, L. A. Metformin inhibits the production of reactive oxygen species from NADH:ubiquinone oxidoreductase to limit induction of interleukin-1β (IL-1β) and boosts interleukin-10 (IL-10) in lipopolysaccharide (LPS)-activated macrophages. J. Biol. Chem. 290, 20348–20359 (2015).
Moiseeva, O. et al. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell 12, 489–498 (2013).
Vasamsetti, S. B. et al. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes 64, 2028–2041 (2015). This study shows the inhibition of monocyte-to-macrophage differentiation and atheromatous plaque formation by metformin in ApoE −/− mice through an AMPK–STAT3-dependent mechanism.
Yan, Z. et al. Metformin suppresses UHMWPE particle-induced osteolysis in the mouse calvaria by promoting polarization of macrophages to an anti-inflammatory phenotype. Mol. Med. 24, 20 (2018).
Buldak, L. et al. Metformin affects macrophages’ phenotype and improves the activity of glutathione peroxidase, superoxide dismutase, catalase and decreases malondialdehyde concentration in a partially AMPK-independent manner in LPS-stimulated human monocytes/macrophages. Pharmacol. Rep. 66, 418–429 (2014).
Arai, M. et al. Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. J. Pharmacol. Exp. Ther. 334, 206–213 (2010).
Stienstra, R., Netea-Maier, R. T., Riksen, N. P., Joosten, L. A. B. & Netea, M. G. Specific and complex reprogramming of cellular metabolism in myeloid cells during innate immune responses. Cell Metab. 26, 142–156 (2017).
Geltink, R. I. K., Kyle, R. L. & Pearce, E. L. Unraveling the complex interplay between T cell metabolism and function. Annu. Rev. Immunol. 36, 461–488 (2018).
Buck, M. D., Sowell, R. T., Kaech, S. M. & Pearce, E. L. Metabolic instruction of immunity. Cell 169, 570–586 (2017).
Negrotto, L., Farez, M. F. & Correale, J. Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol. 73, 520–528 (2016).
Lee, S. Y. et al. Metformin suppresses systemic autoimmunity in Roquin(san/san) mice through inhibiting B cell differentiation into plasma cells via regulation of AMPK/mTOR/STAT3. J. Immunol. 198, 2661–2670 (2017).
Son, H. J. et al. Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis. Mediators Inflamm. 2014, 973986 (2014).
Lee, S. Y. et al. Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17/treg balance. PLOS ONE 10, e0135858 (2015).
Eikawa, S. et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc. Natl Acad. Sci. USA 112, 1809–1814 (2015).
Kunisada, Y. et al. Attenuation of CD4+CD25+ regulatory T cells in the tumor microenvironment by metformin, a type 2 diabetes drug. EBioMedicine 25, 154–164 (2017).
Li, L. et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res. 78, 1779–1791 (2018).
Pereira, F. V. et al. Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. Oncotarget 9, 25808–25825 (2018).
Natali, A. & Ferrannini, E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49, 434–441 (2006).
Wu, T., Horowitz, M. & Rayner, C. K. New insights into the anti-diabetic actions of metformin: from the liver to the gut. Expert Rev. Gastroenterol. Hepatol. 11, 157–166 (2017).
Bonora, E. et al. Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects. Curr. Med. Res. Opin. 9, 47–51 (1984).
Stepensky, D., Friedman, M., Raz, I. & Hoffman, A. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab. Dispos. 30, 861–868 (2002).
Sum, C. F. et al. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet. Med. 9, 61–65 (1992).
Koffert, J. P. et al. Metformin treatment significantly enhances intestinal glucose uptake in patients with type 2 diabetes: results from a randomized clinical trial. Diabetes Res. Clin. Pract. 131, 208–216 (2017).
Wu, T. et al. Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes. Diabetes Obes. Metab. 19, 290–293 (2017).
Bailey, C. J., Wilcock, C. & Day, C. Effect of metformin on glucose metabolism in the splanchnic bed. Br. J. Pharmacol. 105, 1009–1013 (1992).
Penicaud, L., Hitier, Y., Ferre, P. & Girard, J. Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochem. J. 262, 881–885 (1989).
Gontier, E. et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur. J. Nucl. Med. Mol. Imaging 35, 95–99 (2008).
Ikeda, T., Iwata, K. & Murakami, H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem. Pharmacol. 59, 887–890 (2000).
Sakar, Y. et al. Metformin-induced regulation of the intestinal D-glucose transporters. J. Physiol. Pharmacol. 61, 301–307 (2010).
Walker, J. et al. 5-Aminoimidazole-4-carboxamide riboside (AICAR) enhances GLUT2-dependent jejunal glucose transport: a possible role for AMPK. Biochem. J. 385, 485–491 (2005).
Lenzen, S., Lortz, S. & Tiedge, M. Effect of metformin on SGLT1, GLUT2, and GLUT5 hexose transporter gene expression in small intestine from rats. Biochem. Pharmacol. 51, 893–896 (1996).
Bauer, P. V. et al. Metformin alters upper small intestinal microbiota that impact a glucose-SGLT1-sensing glucoregulatory pathway. Cell Metab. 27, 101–117.e5 (2018). This study in rodents shows the effect of metformin on upper small intestinal microbiota and glucose sensing.
Bailey, C. J., Wilcock, C. & Scarpello, J. H. Metformin and the intestine. Diabetologia 51, 1552–1553 (2008).
Duca, F. A. et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat. Med. 21, 506–511 (2015). This paper presents studies in rodent models that show that metformin lowers blood levels of glucose by inhibiting hepatic glucose production through a neuron-mediated gut–brain–liver axis.
Borg, M. J. et al. Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes. Diabetes Obes. Metab. 21, 640–647 (2019).
Henry, R. R. et al. Improved glycemic control with minimal systemic metformin exposure: effects of metformin delayed-release (metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes. PLOS ONE 13, e0203946 (2018).
Oh, J. et al. Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycaemic activity in humans. Diabetes Obes. Metab. 18, 104–108 (2016).
Mannucci, E. et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr. Metab. 17, 336–342 (2004).
Napolitano, A. et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLOS ONE 9, e100778 (2014).
Maida, A., Lamont, B. J., Cao, X. & Drucker, D. J. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 54, 339–349 (2011).
DeFronzo, R. A. et al. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia 59, 1645–1654 (2016).
Bahne, E. et al. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight 3, 93936 (2018). This paper presents human studies that analyse the role of GLP1 release in the glucose-lowering effect of metformin.
Li, M. et al. Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Medicine 96, e8161 (2017).
Bahne, E. et al. Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. Diabetes Obes. Metab. 18, 955–961 (2016).
Mulherin, A. J. et al. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 152, 4610–4619 (2011).
Kim, M. H. et al. Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. J. Endocrinol. 220, 117–128 (2014).
Kappe, C., Patrone, C., Holst, J. J., Zhang, Q. & Sjoholm, A. Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. J. Gastroenterol. 48, 322–332 (2013).
Bronden, A. et al. Single-dose metformin enhances bile acid-induced glucagon-like peptide-1 secretion in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 102, 4153–4162 (2017).
Carter, D., Howlett, H. C., Wiernsperger, N. F. & Bailey, C. J. Differential effects of metformin on bile salt absorption from the jejunum and ileum. Diabetes Obes. Metab. 5, 120–125 (2003).
Lien, F. et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J. Clin. Invest. 124, 1037–1051 (2014).
Hansen, M. et al. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. Diabetes Obes. Metab. 18, 571–580 (2016).
Wu, T. et al. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes Obes. Metab. 15, 474–477 (2013).
Thomas, C. et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10, 167–177 (2009).
Trabelsi, M. S. et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat. Commun. 6, 7629 (2015).
Duca, F. A., Bauer, P. V., Hamr, S. C. & Lam, T. K. Glucoregulatory relevance of small intestinal nutrient sensing in physiology, bariatric surgery, and pharmacology. Cell Metab. 22, 367–380 (2015).
Waise, T. M. Z., Dranse, H. J. & Lam, T. K. T. The metabolic role of vagal afferent innervation. Nat. Rev. Gastroenterol. Hepatol. 15, 625–636 (2018).
Kuhre, R. E., Frost, C. R., Svendsen, B. & Holst, J. J. Molecular mechanisms of glucose-stimulated GLP-1 secretion from perfused rat small intestine. Diabetes 64, 370–382 (2015).
Parker, H. E. et al. Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. Diabetologia 55, 2445–2455 (2012).
Sun, L. et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat. Med. 24, 1919–1929 (2018).
Cote, C. D. et al. Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nat. Med. 21, 498–505 (2015).
Waise, T. M. Z. et al. Inhibition of upper small intestinal mTOR lowers plasma glucose levels by inhibiting glucose production. Nat. Commun. 10, 714 (2019).
Karlsson, F. H. et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498, 99–103 (2013).
Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55–60 (2012).
Lee, H. & Ko, G. Effect of metformin on metabolic improvement and gut microbiota. Appl. Environ. Microbiol. 80, 5935–5943 (2014).
Shin, N. R. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727–735 (2014). These rodent studies show that metformin induces a profound shift in the faecal microbial community profile in HFD-fed mice, with higher abundance of the mucin-degrading bacterium Akkermansia accompanied by an increase in the number of mucin-producing goblet cells and adipose tissue-resident regulatory T cells.
Zhang, X. et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci. Rep. 5, 14405 (2015).
de la Cuesta-Zuluaga, J. et al. Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care 40, 54–62 (2017). These studies in humans show that metformin shifts gut microbiota composition through enrichment of SCFA-producing and mucin-degrading bacteria.
Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850–858 (2017). This study in humans shows that altered gut microbiota mediates some of metformin’s antidiabetic effects in treatment-naive patients with type 2 diabetes mellitus.
Tong, X. et al. Structural alteration of gut microbiota during the amelioration of human type 2 diabetes with hyperlipidemia by metformin and a traditional chinese herbal formula: a multicenter, randomized, open label clinical trial. mBio. 9, e02392-17 (2018).
Rosario, D. et al. Understanding the representative gut microbiota dysbiosis in metformin-treated type 2 diabetes patients using genome-scale metabolic modeling. Front. Physiol. 9, 775 (2018).
De Vadder, F. et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156, 84–96 (2014).
Gibson, G. R. & Roberfroid, M. B. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J. Nutr. 125, 1401–1412 (1995).
Cani, P. D. et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am. J. Clin. Nutr. 90, 1236–1243 (2009).
Chambers, E. S. et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 64, 1744–1754 (2015).
Ridlon, J. M., Kang, D. J. & Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241–259 (2006).
Everard, A. et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl Acad. Sci. USA 110, 9066–9071 (2013).
Plovier, H. et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23, 107–113 (2017).
Depommier, C. et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat. Med. 25, 1096–1103 (2019).
Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).
Vashisht, R. & Brahmachari, S. K. Metformin as a potential combination therapy with existing front-line antibiotics for tuberculosis. J. Transl. Med. 13, 83 (2015).
Cabreiro, F. et al. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 153, 228–239 (2013).
Belkaid, Y. & Harrison, O. J. Homeostatic immunity and the microbiota. Immunity 46, 562–576 (2017).
Postler, T. S. & Ghosh, S. Understanding the holobiont: how microbial metabolites affect human health and shape the immune system. Cell Metab. 26, 110–130 (2017).
McDole, J. R. et al. Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine. Nature 483, 345–349 (2012).
Weisman, A., Bai, J. W., Cardinez, M., Kramer, C. K. & Perkins, B. A. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 5, 501–512 (2017).
Wood, J. R. et al. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care 36, 2035–2037 (2013).
Petrie, J. R. et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 5, 597–609 (2017).
Meng, H. et al. Effect of metformin on glycaemic control in patients with type 1 diabetes: a meta-analysis of randomized controlled trials. Diabetes Metab. Res. Rev. 34, e2983 (2018).
Lund, S. S. et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLOS ONE 3, e3363 (2008).
Scheen, A. J. Will delayed release metformin provide better management of diabetes type 2? Expert Opin. Pharmacother. 17, 627–630 (2016).
Fujita, Y. & Inagaki, N. Metformin: new preparations and nonglycemic benefits. Curr. Diab. Rep. 17, 5 (2017).
Berstein, L. M. Metformin: not only per os. Expert Rev. Endocrinol. Metab. 13, 63–65 (2018).
Cetin, M. & Sahin, S. Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride. Drug Deliv. 23, 2796–2805 (2016).
Zhao, Y. et al. Polymetformin combines carrier and anticancer activities for in vivo siRNA delivery. Nat. Commun. 7, 11822 (2016).
Bouchoucha, M., Uzzan, B. & Cohen, R. Metformin and digestive disorders. Diabetes Metab. 37, 90–96 (2011).
Bonnet, F. & Scheen, A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes. Metab. 19, 473–481 (2017).
McCreight, L. J. et al. Pharmacokinetics of metformin in patients with gastrointestinal intolerance. Diabetes Obes. Metab. 20, 1593–1601 (2018).
Dujic, T. et al. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes 64, 1786–1793 (2015).
Dujic, T., Zhou, K., Tavendale, R., Palmer, C. N. & Pearson, E. R. Effect of serotonin transporter 5-HTTLPR polymorphism on gastrointestinal intolerance to metformin: a GoDARTS study. Diabetes Care 39, 1896–1901 (2016).
Hoffmann, I. S., Roa, M., Torrico, F. & Cubeddu, L. X. Ondansetron and metformin-induced gastrointestinal side effects. Am. J. Ther. 10, 447–451 (2003).
Scarpello, J. H., Hodgson, E. & Howlett, H. C. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet. Med. 15, 651–656 (1998).
Elbere, I. et al. Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. PLOS ONE 13, e0204317 (2018).
Greenway, F., Wang, S. & Heiman, M. A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report. Benef. Microbes 5, 29–32 (2014).
Burton, J. H. et al. Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels. J. Diabetes Sci. Technol. 9, 808–814 (2015).
Escobar-Morreale, H. F. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat. Rev. Endocrinol. 14, 270–284 (2018).
Burt Solorzano, C. M. et al. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids 77, 332–337 (2012).
Ovalle, F. & Azziz, R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil. Steril. 77, 1095–1105 (2002).
Carmina, E. & Lobo, R. A. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil. Steril. 82, 661–665 (2004).
Adashi, E. Y., Hsueh, A. J. & Yen, S. S. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 108, 1441–1449 (1981).
Nestler, J. E. et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J. Clin. Endocrinol. Metab. 83, 2001–2005 (1998).
Carmina, E. et al. The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome. Hum. Reprod. 14, 307–311 (1999).
Tosi, F. et al. Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women. Eur. J. Endocrinol. 164, 197–203 (2011).
Wild, R. A. et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95, 2038–2049 (2010).
Morin-Papunen, L. et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88, 4649–4654 (2003).
Tang, T. et al. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum. Reprod. 21, 80–89 (2006).
Naderpoor, N. et al. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum. Reprod. Update 21, 560–574 (2015).
Orio, F. Jr. et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J. Clin. Endocrinol. Metab. 90, 6072–6076 (2005).
Nestler, J. E., Jakubowicz, D. J., Evans, W. S. & Pasquali, R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med. 338, 1876–1880 (1998).
Lord, J. M., Flight, I. H. & Norman, R. J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst. Rev. 3, CD003053 (2003).
Kashyap, S., Wells, G. A. & Rosenwaks, Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum. Reprod. 19, 2474–2483 (2004).
Legro, R. S. et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 356, 551–566 (2007).
Morley, L. C., Tang, T., Yasmin, E., Norman, R. J. & Balen, A. H. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst. Rev. 11, CD003053 (2017).
Balen, A. H. et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum. Reprod. Update 22, 687–708 (2016).
Heckman-Stoddard, B. M., DeCensi, A., Sahasrabuddhe, V. V. & Ford, L. G. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia 60, 1639–1647 (2017).
Kurelac, I. et al. Inducing cancer indolence by targeting mitochondrial complex I is potentiated by blocking macrophage-mediated adaptive responses. Nat. Commun. 10, 903 (2019).
Rotermund, C., Machetanz, G. & Fitzgerald, J. C. The therapeutic potential of metformin in neurodegenerative diseases. Front. Endocrinol. 9, 400 (2018).
Anisimov, V. N. et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 7, 2769–2773 (2008).
Barzilai, N., Crandall, J. P., Kritchevsky, S. B. & Espeland, M. A. Metformin as a tool to target aging. Cell Metab. 23, 1060–1065 (2016).
Justice, J. N. et al. A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. Geroscience 40, 419–436 (2018).
Degner, N. R., Wang, J. Y., Golub, J. E. & Karakousis, P. C. Metformin use reverses the increased mortality associated with diabetes mellitus during tuberculosis treatment. Clin. Infect. Dis. 66, 198–205 (2018).
Singhal, A. et al. Metformin as adjunct antituberculosis therapy. Sci. Transl. Med. 6, 263ra159 (2014). This study provides evidence for the benefits of metformin treatment as host-adjunctive therapy for improving the effective treatment of tuberculosis.
Rangarajan, S. et al. Metformin reverses established lung fibrosis in a bleomycin model. Nat. Med. 24, 1121–1127 (2018).
Sato, N. et al. Metformin attenuates lung fibrosis development via NOX4 suppression. Respir. Res. 17, 107 (2016).
The authors acknowledge the support of grants from Inserm, CNRS, Université Paris Descartes, Agence Nationale de la Recherche (ANR), Société Francophone du Diabète (SFD), Fondation pour la Recherche Médicale (FRM), the Dutch Organization for Scientific Research (ZonMW) and DiabetesFonds.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Lactic acidosis
A medical condition characterized by excessively low pH in the bloodstream due to excess lactate production by glycolytic tissues, inadequate lactate utilization by gluconeogenic tissues, or varying combinations of these two processes.
The study of the transit of a dosed drug in body fluids and tissues over time, as defined by its rate of absorption, distribution, metabolism and excretion.
The study of the action of a drug in the body, and its biochemical and physiological effects.
- Half-maximal inhibitory concentration
(IC50). The concentration of an inhibitor required to decrease the response of the target by 50%.
- Pyruvate tolerance
A measure of glycaemic excursion in response to an intraperitoneal or intravenous injection of pyruvate, used to assess hepatic gluconeogenesis.
- Cytosolic redox potential
Cytoplasmic oxidation state of the cell, which is assessed by the ratio of reduced to oxidized intracellular metabolite redox couples (for example, lactate/pyruvate ratio).
- Type 2 immune cells
Cells involved in type 2 immune responses, such as type 2 innate lymphoid cells, eosinophils, T helper 2 cells, mast cells, basophils and alternatively-activated macrophages.
- Reverse electron transport
(RET). The transport of electrons from ubiquinol back to respiratory complex 1, generating a substantial amount of reactive oxygen species.
Incretins are gut hormones that are secreted after nutrient intake and stimulate glucose-stimulated insulin secretion.
A non-canonical form of programmed cell death, which is the result of fatty acid over-accumulation that occurs in diseases associated with over-nutrition and ageing.
- Short-chain fatty acid
(SCFA). A fatty acid with fewer than six carbon atoms (for example, acetate, propionate and butyrate) that is the end-product of fermentation of dietary fibres by the anaerobic intestinal microbiota and acts as a signal molecule in the control of mammalian energy metabolism.
About this article
Cite this article
Foretz, M., Guigas, B. & Viollet, B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol 15, 569–589 (2019). https://doi.org/10.1038/s41574-019-0242-2
Metformin combats high glucose-induced damage to the osteogenic differentiation of human periodontal ligament stem cells via inhibition of the NPR3-mediated MAPK pathway
Stem Cell Research & Therapy (2022)
Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study
Reproductive Biology and Endocrinology (2022)
Cell Research (2022)
Metabolic programming in the offspring after gestational overfeeding in the mother: toward neonatal rescuing with metformin in a swine model
International Journal of Obesity (2022)
Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases